Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 17.08.2026 3 AJR Am J Roentgenol 1 Am J Surg 7 Ann Surg Oncol 1 Br J Cancer 1 Breast Cancer 3 Breast Cancer Res 14 Breast Cancer Res Treat 1 Breast J 2 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 6 Cancer Res 1 Carcinogenesis 6 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Cancer 2 Eur Radiol 2 Int J Radiat Oncol Biol Phys 1 J Biol Chem 3 J Natl Cancer Inst 3 J Surg Oncol 1 Nature 1 NPJ Breast Cancer 3 Oncogene 2 Oncol Rep 6 PLoS One 1 Radiol Imaging Cancer 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. CHIKARMANE SA
   The Role of Visual Language Models in the Management of the Axilla in Breast Cancer.
   AJR Am J Roentgenol. 2026 Aug 12. doi: 10.2214/AJR.26.35691.
   PubMed        
   
   
2. XU Y, Heacock L, Park J, Pasadyn FL, et al
   Predicting 5-Year Breast Cancer Risk From Longitudinal Digital Breast Tomosynthesis: A Single-Center Retrospective Study.
   AJR Am J Roentgenol. 2026 Aug 12. doi: 10.2214/AJR.26.34951.
   PubMed         Abstract available
   
   
3. SANDERS J, Panda A, Harper L, Patel B, et al
   Breast MRI in Patients With Active Implanted Metallic Devices: How We Do It.
   AJR Am J Roentgenol. 2026 Mar 25. doi: 10.2214/AJR.26.34661.
   PubMed         Abstract available
   
   

   
   Am J Surg

4. SOLANO OI, Klick S, Baliski C
   Patient reported outcomes associated with multiple approaches to Level 1 oncoplastic breast surgery.
   Am J Surg. 2026;260:117094.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. WAGNER BD, Chen J, Boe LA, Graziano FD, et al
   ASO Visual Abstract: Using Machine Learning to Predict Breast-Cancer-Related Lymphedema following Axillary Lymph Node Dissection.
   Ann Surg Oncol. 2026 Aug 11. doi: 10.1245/s10434-026-20391.
   PubMed        
   
   
6. TAYLOR N, Chew YL, Ng TS, Palesty JA, et al
   ASO Visual Abstract: Recurrence in Real Time: Rethinking Breast Cancer Follow-Up with Circulating Tumor DNA.
   Ann Surg Oncol. 2026 Aug 11. doi: 10.1245/s10434-026-20371.
   PubMed        
   
   
7. KAWASHIMA K, Chida K, Oshi M, Yamada A, et al
   ASO Author Reflections: Neuron Projection Guidance-A transcriptomic perspective on tumor-induced neural recruitment in breast cancer.
   Ann Surg Oncol. 2026 Aug 10. doi: 10.1245/s10434-026-20049.
   PubMed        
   
   
8. GALLOWAY OW, Wilbers A, Sogade OO, Naaseh A, et al
   A Single-Institution Comparative Analysis of Bracketed Localization for Partial Mastectomy Using Traditional Wire and Wireless Methods.
   Ann Surg Oncol. 2026;33:8216-8224.
   PubMed         Abstract available
   
   
9. LORENTZEN EH, Reich AJ, Nguyen K, Minami CA, et al
   Evaluation of Surgeon Attitudes Toward Frailty Screening in Breast Oncology Patients.
   Ann Surg Oncol. 2026;33:8195-8205.
   PubMed         Abstract available
   
   
10. PARK KU, Delisle M, Hassett MJ, Minami CA, et al
    From Clinical Trial Awareness to Practice: Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial.
    Ann Surg Oncol. 2026;33:8165-8174.
    PubMed         Abstract available
    
    
11. BAILEY V, Juckett L, Pessin S, Ghahrai N, et al
    Assessing Recent Trends in Lumpectomy and Concomitant Oncoplastic Procedures: A National Insurance Database Analysis.
    Ann Surg Oncol. 2026;33:8156-8164.
    PubMed         Abstract available
    
    

    
    Br J Cancer

12. YANG Q, Zhang F, Ding Y, Huang J, et al
    Retraction Note: Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer.
    Br J Cancer. 2026 Aug 14. doi: 10.1038/s41416-026-03584.
    PubMed        
    
    

    
    Breast Cancer

13. KUSAMA H, Horimoto Y, Iwai K, Kitaoku Y, et al
    Risk of febrile neutropenia in breast cancer chemotherapy despite the prophylactic use of pegfilgrastim: a retrospective analysis.
    Breast Cancer. 2026 Aug 14. doi: 10.1007/s12282-026-01907.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

14. CHEN WL, Liu WL, Guo CP, Zhu YY, et al
    Intraoperative measurement of breast-conserving surgery margins: surgical application.
    Breast Cancer Res. 2026;28:141.
    PubMed         Abstract available
    
    
15. ACS B, Liu X, Gkekos L, Karlsson E, et al
    Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+/HER2- early breast cancer.
    Breast Cancer Res. 2026;28:139.
    PubMed         Abstract available
    
    
16. ADDISSIE YA, Greer YE, Nair J, Lipkowitz S, et al
    Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer.
    Breast Cancer Res. 2026;28:144.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

17. PINHEIRO LC, An A, Landry CA, Tonorezos E, et al
    Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare.
    Breast Cancer Res Treat. 2026;218:34.
    PubMed         Abstract available
    
    
18. KAWASHIMA K, Elsaedy EA, Oshi M, Yamada A, et al
    Association of tumor Schwann cells with epithelial-mesenchymal transition and immune-suppressive microenvironment in triple-negative breast cancer.
    Breast Cancer Res Treat. 2026;218:37.
    PubMed         Abstract available
    
    
19. BITSIE KR, Pearson TA, Kwan ML, Yaghjyan L, et al
    Self-reported racial and ethnic discrimination in patient-provider interactions and the initiation of adjuvant therapies for breast cancer in the pathways study.
    Breast Cancer Res Treat. 2026;218:36.
    PubMed         Abstract available
    
    
20. MARGOLIS S, Guirguis AN, Lee C, Smith S, et al
    Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?
    Breast Cancer Res Treat. 2026;218:35.
    PubMed         Abstract available
    
    
21. LIU J, Liu L, Yague E, Yang Q, et al
    Retraction Note: GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
    Breast Cancer Res Treat. 2026;218:39.
    PubMed        
    
    
22. KHAJEH M, Shahram MA
    The emerging role of artificial intelligence in preoperative prediction of surgical margin status in breast cancer surgery.
    Breast Cancer Res Treat. 2026;218:38.
    PubMed        
    
    
23. GUYON C, Guffroy F, Sabah J, Mossino Diaz L, et al
    Breast skin ulceration in de novo metastatic breast cancer: incidence, predictors, and patterns of occurrence.
    Breast Cancer Res Treat. 2026;218:42.
    PubMed         Abstract available
    
    
24. SHERN TP, Chamberlain V, Holt LR, Gadd MA, et al
    When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction.
    Breast Cancer Res Treat. 2026;218:40.
    PubMed         Abstract available
    
    
25. LYNCE F, Ru M, Luo L, Miranda M, et al
    Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.
    Breast Cancer Res Treat. 2026;218:41.
    PubMed         Abstract available
    
    
26. YANG TWW, Rose AK, Matheson J, Elder K, et al
    Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging.
    Breast Cancer Res Treat. 2026;218:45.
    PubMed         Abstract available
    
    
27. BENDER U, Ronan K, Aljuhani A, Savill J, et al
    The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.
    Breast Cancer Res Treat. 2026;218:43.
    PubMed         Abstract available
    
    
28. KOLLATOS C, Pantiora E, Jazrawi A, Warnberg F, et al
    Factors associated with discordance between pathological and radiological tumor size and risk of re-excision in breast-conserving surgery: a post-hoc analysis within a randomized trial.
    Breast Cancer Res Treat. 2026;218:46.
    PubMed         Abstract available
    
    
29. HAN K, Zhao C
    Comment on "Effects of a sensorimotor-based, movement quality-focused intervention on functional mobility in breast cancer survivors: a multicenter randomized controlled trial".
    Breast Cancer Res Treat. 2026;218:47.
    PubMed         Abstract available
    
    
30. JOHNSON HM, Dong W, Shen Y, Irish W, et al
    Validation of a novel prognostic staging system for breast cancer incorporating age at diagnosis.
    Breast Cancer Res Treat. 2026;218:44.
    PubMed         Abstract available
    
    

    
    Breast J

31. ZHANG XX, Guo H, Li HY, Zhou XT, et al
    rs2357322 and rs17726078 Contribute to Breast Cancer Risk by Regulating DLX2 Expression.
    Breast J. 2026;2026:e3096873.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

32. XU B, Yang J, Zhang P, Wang W, et al
    A phase 1, open-label study evaluating the pharmacokinetics, safety, and tolerability of vepdegestrant in Chinese patients with ER+/HER2- advanced breast cancer.
    Cancer Chemother Pharmacol. 2026;96:90.
    PubMed         Abstract available
    
    
33. LIGERTWOOD S, Ayeni FE, Parsonson A, Edirimanne S, et al
    Associations of body composition with neoadjuvant chemotherapy response, toxicity, and prognosis in breast cancer: a scoping review.
    Cancer Chemother Pharmacol. 2026;96:89.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

34. THOMPSON CN, Luo I, Satoyoshi M, Kenkare P, et al
    Peripheral Absolute Lymphocyte Count, Breast Cancer-Specific and Overall Mortality According to Race, Ethnicity, and Breast Cancer Subtypes.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed         Abstract available
    
    

    
    Cancer Lett

35. LIAO Y, Yin S, Peng EY, Wu J, et al
    The GCN5L2-SIX1 complex drives glycolysis to promote progression of triple-negative breast cancer.
    Cancer Lett. 2026 Aug 14:218770. doi: 10.1016/j.canlet.2026.218770.
    PubMed         Abstract available
    
    

    
    Cancer Res

36. WU L, Xu Z, Wang J, Liu F, et al
    ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis Through Symbiotic Adhesion and Reverse Migration.
    Cancer Res. 2026;86:4007-4027.
    PubMed         Abstract available
    
    
37. PUTELO AM, Bajgai S, Poblete MK, Guido G, et al
    Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination.
    Cancer Res. 2026;86:4063-4079.
    PubMed         Abstract available
    
    
38. SUDHAKARAN M, Kersten K
    Motherhood's sentinels: Pregnancy induces tissue-resident memory T cells to curb breast cancer growth.
    Cancer Res. 2026 Aug 10. doi: 10.1158/0008-5472.CAN-26-3367.
    PubMed         Abstract available
    
    
39. GONZALEZ E, Kreger J, Liu Y, Wu X, et al
    Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer.
    Cancer Res. 2026 Aug 11. doi: 10.1158/0008-5472.CAN-26-1086.
    PubMed         Abstract available
    
    
40. ZHANG J, Li N, Li R, Chen Y, et al
    Fasting-Mimicking Diets Reprogram Cancer-Associated Fibroblasts to Reverse the Immunosuppressive Tumor Microenvironment in Breast Cancer.
    Cancer Res. 2026 Aug 11. doi: 10.1158/0008-5472.CAN-25-5945.
    PubMed         Abstract available
    
    
41. SUTCLIFFE MD, Mott KR, Yilmaz-Swenson T, Felsheim BM, et al
    Transcriptomic Profiling of Mouse Mammary Tumors Enables Prognostic and Predictive Biomarker Discovery for Human Breast Cancer.
    Cancer Res. 2026 Aug 14. doi: 10.1158/0008-5472.CAN-26-0855.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

42. ALNOUBANI Z, Khanafer Y, Fojnica A, Begagic E, et al
    The prevalence of the AR-V7 variant and its association with clinicopathologic characteristics in non-prostatic cancers-a systematic review.
    Carcinogenesis. 2026;47:bgag052.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

43. SPIL J, de Groot LG, Kwee E, Mureau MAM, et al
    Neuropathic Pain Prevalence After Axillary Procedures in Breast Cancer: A Systematic Review and Meta-analysis.
    Clin Breast Cancer. 2026;26:31-38.
    PubMed         Abstract available
    
    
44. WANG AJ, Kagan S, Zhang L, Hircock C, et al
    Retrospective Analysis of Acute Toxicity Following Breast Cancer Re-Irradiation.
    Clin Breast Cancer. 2026;26:25-30.
    PubMed         Abstract available
    
    
45. GUO Y, Xiao Y, Song Z, Yang J, et al
    Unraveling Time-Varying Effects of Risk Factors for Contralateral Invasive Breast Cancer Following Ductal Carcinoma In Situ.
    Clin Breast Cancer. 2026;26:14-24.
    PubMed         Abstract available
    
    
46. REDDY H, Lopez-May M, Berkalieva A, Moshier E, et al
    Predictors of Surgical Decision-Making After Neoadjuvant Chemotherapy for Breast Cancer.
    Clin Breast Cancer. 2026;26:39-43.
    PubMed         Abstract available
    
    
47. ONDER T, Ates O
    Phenotypic Age Acceleration Predicts Survival Outcomes in HR(+)/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study.
    Clin Breast Cancer. 2026;26:53-61.
    PubMed         Abstract available
    
    
48. ANGELICO F, Peleteiro B, Osorio F
    The American Joint Committee on Cancer Prognostic Staging System for Breast Cancer: Sustained Relevance of Anatomic Criteria on 5-Year Survival.
    Clin Breast Cancer. 2026;26:75-83.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

49. JHAVERI K, Rugo HS, Cortes J, Oliveira M, et al
    Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.
    Clin Cancer Res. 2026;32:3599-3607.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

50. BERNSTEIN-MOLHO R, Sella T, Delucchi V, Coussy F, et al
    Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer.
    Eur J Cancer. 2026;245:116937.
    PubMed         Abstract available
    
    

    
    Eur Radiol

51. LARSEN M, Moshina N, Mikalsen KO, Hoff SR, et al
    Mammographic density assessment by an artificial intelligence model for breast cancer detection in BreastScreen Norway.
    Eur Radiol. 2026 Aug 13. doi: 10.1007/s00330-026-12786.
    PubMed         Abstract available
    
    
52. SAYGILI OZ D
    Letter to the Editor: Axillary radiological complete response in HER2-positive breast cancer: toward validated decision support.
    Eur Radiol. 2026 Aug 14. doi: 10.1007/s00330-026-12815.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

53. BEHZADI ST, Wider J, Nano J, Kiesl S, et al
    Response to neoadjuvant chemotherapy as a potential indicator of internal mammary node involvement in early breast cancer.
    Int J Radiat Oncol Biol Phys. 2026 Aug 10:S0360-3016(26)04145.
    PubMed         Abstract available
    
    
54. HOGSBJERG KW, Petersen SE, Maae E, Matthiessen LW, et al
    Acute radiation side effects of proton versus photon therapy following surgery for early breast cancer, a sub-study of the randomised controlled DBCG Proton Trial.
    Int J Radiat Oncol Biol Phys. 2026 Aug 14:S0360-3016(26)04156.
    PubMed         Abstract available
    
    

    
    J Biol Chem

55. LERO MW, Morgan JS, Card MA, Zhu LJ, et al
    Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer.
    J Biol Chem. 2026 Aug 10:113426. doi: 10.1016/j.jbc.2026.113426.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

56. AGOSTINETTO E, Gentile G, Samy F, Di Cosimo S, et al
    The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.
    J Natl Cancer Inst. 2026;118:1504-1513.
    PubMed         Abstract available
    
    
57. LAMMERS EM, Zijlstra JM, Schaapveld M, Haagsma JA, et al
    The impact of survivorship care on burden of disease among Hodgkin lymphoma survivors.
    J Natl Cancer Inst. 2026 Apr 11:djag080. doi: 10.1093.
    PubMed         Abstract available
    
    
58. ARECCO L, Blondeaux E, Bruzzone M, de Azambuja E, et al
    Refining risk stratification of patients with early breast cancer eligible for adjuvant abemaciclib or ribociclib.
    J Natl Cancer Inst. 2026 Aug 14:djag264. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

59. OTERO-ROMERO D, Carraminana-Nuno R, Arribas-Del-Amo D
    Sentinel Lymph Node Biopsy in Elderly Patients With Aggressive Breast Cancer Subtypes: Real-World Clinical Utility and Treatment Implications.
    J Surg Oncol. 2026 Aug 10. doi: 10.1002/jso.70364.
    PubMed         Abstract available
    
    
60. GAUR KS, Conroy MM, Rein LE, Szabo A, et al
    Assessing Time to Surgery in Asian Women With Breast Cancer: A National Cancer Database Analysis.
    J Surg Oncol. 2026 Aug 10. doi: 10.1002/jso.70368.
    PubMed         Abstract available
    
    
61. ABDULLA HA, Matthew M, Zaborowski AM, Rutherford CL, et al
    Assessment of the Impact of Chemotherapeutic 'Treatment Effect' on Oncological Outcomes in Initially Node-Positive Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy Only After Neoadjuvant Chemotherapy.
    J Surg Oncol. 2026 Aug 10. doi: 10.1002/jso.70369.
    PubMed         Abstract available
    
    

    
    Nature

62. WATT AC, Ahn A, Blyth C, Dixon-Douglas JR, et al
    Rb-driven transcription limits its tumour-suppressive effects in breast cancer.
    Nature. 2026 Aug 12. doi: 10.1038/s41586-026-10886.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

63. SASIAIN I, Nacer DF, Jonsson M, Vallon-Christersson J, et al
    Genome-wide DNA methylation profiling of triple-negative breast cancer uncovers epigenetic biomarkers of tumor identity and the immune microenvironment.
    NPJ Breast Cancer. 2026;12:105.
    PubMed         Abstract available
    
    

    
    Oncogene

64. GONG C, Qu S, Liu B, Pan S, et al
    Correction to: MiR-106b expression determines the proliferation paradox of TGF-beta in breast cancer cells.
    Oncogene. 2026 Aug 10. doi: 10.1038/s41388-026-03954.
    PubMed        
    
    
65. DUAN Y, Alexandrou AT, Huang J, Zhang HS, et al
    Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression.
    Oncogene. 2026 Aug 12. doi: 10.1038/s41388-026-03941.
    PubMed         Abstract available
    
    
66. TANG C, Su K, Zhan Z, Huang R, et al
    Inhibition of PINK1/Parkin-mediated mitophagy enhances the susceptibility of breast cancer to cuproptosis.
    Oncogene. 2026 Aug 13. doi: 10.1038/s41388-026-03945.
    PubMed         Abstract available
    
    

    
    Oncol Rep

67. YANG Z, Liu Y, Shi C, Zhang Y, et al
    [Expression of Concern] Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways.
    Oncol Rep. 2026;56:173.
    PubMed         Abstract available
    
    
68. ZENG J, Hu J, Ma Z, Zhu S, et al
    Polyphenol?based interventions in breast cancer: Signaling pathways, molecular mechanisms and translational therapeutic strategies (Review).
    Oncol Rep. 2026;56:170.
    PubMed         Abstract available
    
    

    
    PLoS One

69. YAMASHITA PR, Tangthanawatsakul A, Termsaithong T, Roshorm YM, et al
    Integrating dynamic modeling of signaling pathways with subject-specific transcriptomic data to assess breast cancer risk.
    PLoS One. 2026;21:e0355838.
    PubMed         Abstract available
    
    
70. GERNIER F, Lequesne J, Grellard JM, Fernette M, et al
    Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation.
    PLoS One. 2026;21:e0354676.
    PubMed         Abstract available
    
    
71. VU LT, Vu LT, Vu LTK, Pho HTT, et al
    Mechanistic insights into daidzin from Glycine max against breast cancer via network pharmacology and multi-level molecular modeling.
    PLoS One. 2026;21:e0355672.
    PubMed         Abstract available
    
    
72. SARMEILI F, Ghahremani-Nezhad B, Khalilpour M, Abbasi K, et al
    Shedding light on neural learning to rank models for anticancer drug prioritization.
    PLoS One. 2026;21:e0345854.
    PubMed         Abstract available
    
    
73. CHENG C, McGregor BA, Hur J, Combs CK, et al
    Bidirectional phenotypic transition in macrophages influences triple-negative breast cancer cell immune evasive patterns and response to chemotherapies in a co-culture spheroid model.
    PLoS One. 2026;21:e0356198.
    PubMed         Abstract available
    
    
74. TAO L, Li M, Lv J, Wang Q, et al
    Influence of psychosocial adaptation on existential distress among young breast cancer survivors in the rehabilitation period: An analysis of the chain mediating effects of social support and psychological resilience.
    PLoS One. 2026;21:e0354635.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

75. CHEN S, Chen Y, Jin C, Zheng B, et al
    Incremental Value of Synthetic MRI Radiomics in Predicting Neoadjuvant Response in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Radiol Imaging Cancer. 2026;8:e250758.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

76. HONG SW, Kim EK, Shin HC, Beom J, et al
    Dosimetric parameters of the axillary-lateral thoracic junction in predicting risk of breast cancer-related lymphedema.
    Radiother Oncol. 2026 Aug 13:111725. doi: 10.1016/j.radonc.2026.111725.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum